vTv Therapeutics (NASDAQ:VTVT) shares reached a new 52-week high and low during trading on Friday . The stock traded as low as $3.35 and last traded at $3.42, with a volume of 278725 shares traded. The stock had previously closed at $3.69.
Several research firms have recently commented on VTVT. Seaport Global Securities began coverage on vTv Therapeutics in a research report on Thursday, March 29th. They issued a “buy” rating and a $14.00 price target for the company. Roth Capital began coverage on vTv Therapeutics in a research report on Thursday, March 8th. They issued a “buy” rating and a $17.00 price target for the company. Zacks Investment Research lowered vTv Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, March 3rd. Northland Securities began coverage on vTv Therapeutics in a research report on Thursday, February 8th. They issued an “outperform” rating and a $28.00 price target for the company. Finally, Canaccord Genuity set a $15.00 price target on vTv Therapeutics and gave the stock a “buy” rating in a research report on Thursday, December 21st. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and six have issued a buy rating to the company. vTv Therapeutics has a consensus rating of “Buy” and a consensus price target of $15.07.
The company has a quick ratio of 0.76, a current ratio of 0.76 and a debt-to-equity ratio of -0.10. The stock has a market capitalization of $121.08, a P/E ratio of -2.05 and a beta of 1.74.
vTv Therapeutics (NASDAQ:VTVT) last announced its earnings results on Tuesday, February 27th. The biotechnology company reported ($0.44) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.41) by ($0.03). The company had revenue of $0.23 million during the quarter, compared to analysts’ expectations of $0.10 million. equities analysts anticipate that vTv Therapeutics will post -1.48 EPS for the current year.
A number of hedge funds have recently made changes to their positions in the stock. Millennium Management LLC purchased a new position in vTv Therapeutics during the 4th quarter worth $377,000. Royce & Associates LP purchased a new position in vTv Therapeutics during the 4th quarter worth $1,352,000. Creative Planning purchased a new position in vTv Therapeutics during the 4th quarter worth $114,000. JPMorgan Chase & Co. purchased a new position in vTv Therapeutics during the 3rd quarter worth $481,000. Finally, State Street Corp grew its stake in vTv Therapeutics by 2.1% during the 2nd quarter. State Street Corp now owns 98,016 shares of the biotechnology company’s stock worth $486,000 after buying an additional 1,976 shares during the last quarter. Hedge funds and other institutional investors own 11.20% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This story was first reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this story on another domain, it was illegally copied and reposted in violation of US and international trademark and copyright legislation. The correct version of this story can be accessed at https://www.dispatchtribunal.com/2018/04/08/vtv-therapeutics-vtvt-reaches-new-12-month-high-and-low-at-3-35.html.
About vTv Therapeutics
vTv Therapeutics Inc, a clinical-stage biopharmaceutical company, discovers, develops, and sells orally administered small molecule drug candidates worldwide. The company's drug candidates comprise azeliragon (TTP488), an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts, which is in Phase III clinical trials for the treatment of Alzheimer's disease.
Receive News & Ratings for vTv Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for vTv Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.